Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia 19Leukemia, Myeloid, Chronic-Phase 16Breast Neoplasms 11Neoplasm Metastasis 10Leukemia, Myeloid, Acute 8Blast Crisis 8Prostatic Neoplasms 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Recurrence 5Pancreatic Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Melanoma 4Gliosarcoma 4Glioblastoma 4Rectal Neoplasms 3Philadelphia Chromosome 3Lung Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2

Interventions

fludarabine phosphate 38Cyclophosphamide 37Peripheral Blood Stem Cell Transplantation 32Busulfan 28Tacrolimus 26Whole-Body Irradiation 20Mycophenolic Acid 19Methotrexate 17Antilymphocyte Serum 17ruxolitinib 16fludarabine 14Filgrastim 13Cyclosporine 12Melphalan 11Radiotherapy 9Etoposide 9thymoglobulin 8Psychiatric Rehabilitation 8Prednisone 8Methylprednisolone 8Cytarabine 6Cord Blood Stem Cell Transplantation 6Thiotepa 5Sirolimus 5Imatinib Mesylate 5Flow Cytometry 5Azacitidine 5Alemtuzumab 5sargramostim 4merphos 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Primary Myelofibrosis × Dasatinib × Clear all
NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡